A Bioscience Stock for Growth Portfolios

Pacira Some of the best performers in 2019’s stock market were bioscience stocks, and we could see a similar trend this year. Investors who are looking for strong growth picks will need to find companies that offer innovative solutions to major health problems. Pacira BioSciences Inc. (NASDAQ: PCRX) is one option that looks particularly promising.

7 of the Biggest Mistakes People Make When Choosing a Financial Advisor Learn More

Pacira develops non-opioid pain medications. These solutions are in high demand, especially considering the ongoing opioid epidemic in the United States. Patients can now get access to effective pain management without exposure to dangerous and potentially addictive drugs.

Annual revenue for Pacira has increased in every year since 2014. In the previous fiscal year, revenue was up 17.67%, with gross income up 26.03%. Profitability is high, especially when considering that the company invests heavily in research and development. The gross profit margin was 74.25% in the previous fiscal year, and EBITDA is positive at 11.19%.

In the current fiscal year, Pacira’s earnings growth is expected to be close to 49%. This projection compares favorably with the 10% expected for the wider Medical-Drugs industry.

A current price target of $55.86 hints at a strong upside for investors who buy in February.

Key Data:

  • 1 Year Price Growth:  74%
  • YTD Price Growth: -0.53%
  • 3 Month Price Growth: 32%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.

 

The reports, research and newsletter are based on current and historical market data, as well as publicly available financial data.They are intended to be a starting point for investors. They do not provide every material fact about a company or industry, nor are they recommendations to buy or sell. The writers and the company make no warranties or representations as to the accuracy of these reports.   You should NOT rely solely upon the information or opinions read in the content. Rather, you should use the content as a starting point for doing independent research on the independent analysis and trading methods in the content. The content is impersonal and does not provide individualized advice or recommendations for any specific reader or individual portfolio. By accessing this website you have agreed to our disclaimers and privacy policy.

 

 

The reports, research and newsletter are based on current and historical market data, as well as publicly available financial data.They are intended to be a starting point for investors. They do not provide every material fact about a company or industry, nor are they recommendations to buy or sell. The writers and the company make no warranties or representations as to the accuracy of these reports.   You should NOT rely solely upon the information or opinions read in the content. Rather, you should use the content as a starting point for doing independent research on the independent analysis and trading methods in the content. The content is impersonal and does not provide individualized advice or recommendations for any specific reader or individual portfolio. By accessing this website you have agreed to our disclaimers and privacy policy.

 

You May Also Like